Evidence map›Paper›PMID 36296283›Full record

ReviewMicroorganisms2022

Secondary Metabolites Produced by Plant Growth-Promoting Bacterial Endophytes.

Zareen Narayanan, Bernard R Glick

Abstract readReview
In one paragraph

Review in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Genomic insights and evaluation ofFrontiers in cellular and infection microbiology · 2026
    Article
  11. Article
  12. Isolation and Identification of EndophyticJournal of fungi (Basel, Switzerland) · 2025
    Article
  13. Article
  14. Article
  15. Evaluating the toxicity and efficacy of the endophytic bacteriumBiochemistry and biophysics reports · 2025
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zareen NarayananDivision of Biological Sciences, School of STEM, University of Washington, Bothell, WA 98011, USA.
Bernard R GlickDepartment of Biology, University of Waterloo, Waterloo, ON N2L3G1, Canada.ORCID 0000-0002-1729-4258

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is an increasing interest in the use of beneficial microorganisms as alternatives to chemically synthesized or plant-derived molecules to produce therapeutic agents. Bacterial endophytes are plant-associated microorganisms that can colonize different parts of living plants without causing any diseases. Diverse endophytic bacteria possess the ability to synthesize a wide range of secondary metabolites with unique chemical structures that have been exploited for their anti-microbial, antiviral, anti-cancer, and anti-inflammatory properties. Additionally, production of these bioactive compounds can also benefit the host plant as they may play a significant role in a plant's interaction with the environment for adaptation and defense. As a result of their significant impact as curative compounds or as precursors to produce new drugs, the biotechnological possibilities of secondary metabolites derived from endophytic bacteria are immense.

Indexed as

endophytesmechanismsplant growth promoting bacteriasecondary metabolitestherapeutic applications

Identifiers

PMID36296283
PMCPMC9610442

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.